Consecutive prediction of adverse maternal outcomes of preeclampsia, using the PIERS-ML and fullPIERS models: A multicountry prospective observational study.

<h4>Background</h4>Preeclampsia is a potentially life-threatening pregnancy complication. Among women whose pregnancies are complicated by preeclampsia, the Preeclampsia Integrated Estimate of RiSk (PIERS) models (i.e., the PIERS Machine Learning [PIERS-ML] model, and the logistic regres...

Full description

Saved in:
Bibliographic Details
Main Authors: Guiyou Yang, Tünde Montgomery-Csobán, Wessel Ganzevoort, Sanne J Gordijn, Kimberley Kavanagh, Paul Murray, Laura A Magee, Henk Groen, Peter von Dadelszen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-02-01
Series:PLoS Medicine
Online Access:https://doi.org/10.1371/journal.pmed.1004509
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823864110688763904
author Guiyou Yang
Tünde Montgomery-Csobán
Wessel Ganzevoort
Sanne J Gordijn
Kimberley Kavanagh
Paul Murray
Laura A Magee
Henk Groen
Peter von Dadelszen
author_facet Guiyou Yang
Tünde Montgomery-Csobán
Wessel Ganzevoort
Sanne J Gordijn
Kimberley Kavanagh
Paul Murray
Laura A Magee
Henk Groen
Peter von Dadelszen
author_sort Guiyou Yang
collection DOAJ
description <h4>Background</h4>Preeclampsia is a potentially life-threatening pregnancy complication. Among women whose pregnancies are complicated by preeclampsia, the Preeclampsia Integrated Estimate of RiSk (PIERS) models (i.e., the PIERS Machine Learning [PIERS-ML] model, and the logistic regression-based fullPIERS model) accurately identify individuals at greatest or least risk of adverse maternal outcomes within 48 h following admission. Both models were developed and validated to be used as part of initial assessment. In the United Kingdom, the National Institute for Health and Care Excellence (NICE) recommends repeated use of such static models for ongoing assessment beyond the first 48 h. This study evaluated the models' performance during such consecutive prediction.<h4>Methods and findings</h4>This multicountry prospective study used data of 8,843 women (32% white, 30% black, and 26% Asian) with a median age of 31 years. These women, admitted to maternity units in the Americas, sub-Saharan Africa, South Asia, Europe, and Oceania, were diagnosed with preeclampsia at a median gestational age of 35.79 weeks between year 2003 and 2016. The risk differentiation performance of the PIERS-ML and fullPIERS models were assessed for each day within a 2-week post-admission window. The PIERS adverse maternal outcome includes one or more of: death, end-organ complication (cardiorespiratory, renal, hepatic, etc.), or uteroplacental dysfunction (e.g., placental abruption). The main outcome measures were: trajectories of mean risk of each of the uncomplicated course and adverse outcome groups; daily area under the precision-recall curve (AUC-PRC); potential clinical impact (i.e., net benefit in decision curve analysis); dynamic shifts of multiple risk groups; and daily likelihood ratios. In the 2 weeks window, the number of daily outcome events decreased from over 200 to around 10. For both PIERS-ML and fullPIERS models, we observed consistently higher mean risk in the adverse outcome (versus uncomplicated course) group. The AUC-PRC values (0.2-0.4) of the fullPIERS model remained low (i.e., close to the daily fraction of adverse outcomes, indicating low discriminative capacity). The PIERS-ML model's AUC-PRC peaked on day 0 (0.65), and notably decreased thereafter. When categorizing women into multiple risk groups, the PIERS-ML model generally showed good rule-in capacity for the "very high" risk group, with positive likelihood ratio values ranging from 70.99 to infinity, and good rule-out capacity for the "very low" risk group where most negative likelihood ratio values were 0. However, performance declined notably for other risk groups beyond 48 h. Decision curve analysis revealed a diminishing advantage for treatment guided by both models over time. The main limitation of this study is that the baseline performance of the PIERS-ML model was assessed on its development data; however, its baseline performance has also undergone external evaluation.<h4>Conclusions</h4>In this study, we have evaluated the performance of the fullPIERS and PIERS-ML models for consecutive prediction. We observed deteriorating performance of both models over time. We recommend using the models for consecutive prediction with greater caution and interpreting predictions with increasing uncertainty as the pregnancy progresses. For clinical practice, models should be adapted to retain accuracy when deployed serially. The performance of future models can be compared with the results of this study to quantify their added value.
format Article
id doaj-art-b2c8bd0ec6bc467d8058dc5295fb30a4
institution Kabale University
issn 1549-1277
1549-1676
language English
publishDate 2025-02-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Medicine
spelling doaj-art-b2c8bd0ec6bc467d8058dc5295fb30a42025-02-09T05:30:23ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762025-02-01222e100450910.1371/journal.pmed.1004509Consecutive prediction of adverse maternal outcomes of preeclampsia, using the PIERS-ML and fullPIERS models: A multicountry prospective observational study.Guiyou YangTünde Montgomery-CsobánWessel GanzevoortSanne J GordijnKimberley KavanaghPaul MurrayLaura A MageeHenk GroenPeter von Dadelszen<h4>Background</h4>Preeclampsia is a potentially life-threatening pregnancy complication. Among women whose pregnancies are complicated by preeclampsia, the Preeclampsia Integrated Estimate of RiSk (PIERS) models (i.e., the PIERS Machine Learning [PIERS-ML] model, and the logistic regression-based fullPIERS model) accurately identify individuals at greatest or least risk of adverse maternal outcomes within 48 h following admission. Both models were developed and validated to be used as part of initial assessment. In the United Kingdom, the National Institute for Health and Care Excellence (NICE) recommends repeated use of such static models for ongoing assessment beyond the first 48 h. This study evaluated the models' performance during such consecutive prediction.<h4>Methods and findings</h4>This multicountry prospective study used data of 8,843 women (32% white, 30% black, and 26% Asian) with a median age of 31 years. These women, admitted to maternity units in the Americas, sub-Saharan Africa, South Asia, Europe, and Oceania, were diagnosed with preeclampsia at a median gestational age of 35.79 weeks between year 2003 and 2016. The risk differentiation performance of the PIERS-ML and fullPIERS models were assessed for each day within a 2-week post-admission window. The PIERS adverse maternal outcome includes one or more of: death, end-organ complication (cardiorespiratory, renal, hepatic, etc.), or uteroplacental dysfunction (e.g., placental abruption). The main outcome measures were: trajectories of mean risk of each of the uncomplicated course and adverse outcome groups; daily area under the precision-recall curve (AUC-PRC); potential clinical impact (i.e., net benefit in decision curve analysis); dynamic shifts of multiple risk groups; and daily likelihood ratios. In the 2 weeks window, the number of daily outcome events decreased from over 200 to around 10. For both PIERS-ML and fullPIERS models, we observed consistently higher mean risk in the adverse outcome (versus uncomplicated course) group. The AUC-PRC values (0.2-0.4) of the fullPIERS model remained low (i.e., close to the daily fraction of adverse outcomes, indicating low discriminative capacity). The PIERS-ML model's AUC-PRC peaked on day 0 (0.65), and notably decreased thereafter. When categorizing women into multiple risk groups, the PIERS-ML model generally showed good rule-in capacity for the "very high" risk group, with positive likelihood ratio values ranging from 70.99 to infinity, and good rule-out capacity for the "very low" risk group where most negative likelihood ratio values were 0. However, performance declined notably for other risk groups beyond 48 h. Decision curve analysis revealed a diminishing advantage for treatment guided by both models over time. The main limitation of this study is that the baseline performance of the PIERS-ML model was assessed on its development data; however, its baseline performance has also undergone external evaluation.<h4>Conclusions</h4>In this study, we have evaluated the performance of the fullPIERS and PIERS-ML models for consecutive prediction. We observed deteriorating performance of both models over time. We recommend using the models for consecutive prediction with greater caution and interpreting predictions with increasing uncertainty as the pregnancy progresses. For clinical practice, models should be adapted to retain accuracy when deployed serially. The performance of future models can be compared with the results of this study to quantify their added value.https://doi.org/10.1371/journal.pmed.1004509
spellingShingle Guiyou Yang
Tünde Montgomery-Csobán
Wessel Ganzevoort
Sanne J Gordijn
Kimberley Kavanagh
Paul Murray
Laura A Magee
Henk Groen
Peter von Dadelszen
Consecutive prediction of adverse maternal outcomes of preeclampsia, using the PIERS-ML and fullPIERS models: A multicountry prospective observational study.
PLoS Medicine
title Consecutive prediction of adverse maternal outcomes of preeclampsia, using the PIERS-ML and fullPIERS models: A multicountry prospective observational study.
title_full Consecutive prediction of adverse maternal outcomes of preeclampsia, using the PIERS-ML and fullPIERS models: A multicountry prospective observational study.
title_fullStr Consecutive prediction of adverse maternal outcomes of preeclampsia, using the PIERS-ML and fullPIERS models: A multicountry prospective observational study.
title_full_unstemmed Consecutive prediction of adverse maternal outcomes of preeclampsia, using the PIERS-ML and fullPIERS models: A multicountry prospective observational study.
title_short Consecutive prediction of adverse maternal outcomes of preeclampsia, using the PIERS-ML and fullPIERS models: A multicountry prospective observational study.
title_sort consecutive prediction of adverse maternal outcomes of preeclampsia using the piers ml and fullpiers models a multicountry prospective observational study
url https://doi.org/10.1371/journal.pmed.1004509
work_keys_str_mv AT guiyouyang consecutivepredictionofadversematernaloutcomesofpreeclampsiausingthepiersmlandfullpiersmodelsamulticountryprospectiveobservationalstudy
AT tundemontgomerycsoban consecutivepredictionofadversematernaloutcomesofpreeclampsiausingthepiersmlandfullpiersmodelsamulticountryprospectiveobservationalstudy
AT wesselganzevoort consecutivepredictionofadversematernaloutcomesofpreeclampsiausingthepiersmlandfullpiersmodelsamulticountryprospectiveobservationalstudy
AT sannejgordijn consecutivepredictionofadversematernaloutcomesofpreeclampsiausingthepiersmlandfullpiersmodelsamulticountryprospectiveobservationalstudy
AT kimberleykavanagh consecutivepredictionofadversematernaloutcomesofpreeclampsiausingthepiersmlandfullpiersmodelsamulticountryprospectiveobservationalstudy
AT paulmurray consecutivepredictionofadversematernaloutcomesofpreeclampsiausingthepiersmlandfullpiersmodelsamulticountryprospectiveobservationalstudy
AT lauraamagee consecutivepredictionofadversematernaloutcomesofpreeclampsiausingthepiersmlandfullpiersmodelsamulticountryprospectiveobservationalstudy
AT henkgroen consecutivepredictionofadversematernaloutcomesofpreeclampsiausingthepiersmlandfullpiersmodelsamulticountryprospectiveobservationalstudy
AT petervondadelszen consecutivepredictionofadversematernaloutcomesofpreeclampsiausingthepiersmlandfullpiersmodelsamulticountryprospectiveobservationalstudy